Intuitive Machines, Inc.

Executive Summary

SELL, Medium conviction. Rated SELL, Medium conviction. The company has real commercial momentum, shown by $1.8B backlog, $1.7B bookings YTD, and FY26 revenue guidance of $900M-$1.0B, but the stock still trades at 4.61x sales while FY2025 operating margin was -28.5%, net margin was -90.8%, and earnings misses have been persistent. With shares already -66.6% below the 52-week high, the debate is no longer about survival, it is about whether the current valuation properly discounts heavy contract timing risk, cash burn, and still-unproven durable profitability.

Investment Thesis

LUNR has a real business. That matters, because many speculative space names never get past a story. Intuitive Machines now has $1.8B backlog, $1.7B bookings YTD, and management is guiding to $900M-$1.0B of FY26 revenue while still expecting positive adjusted EBITDA. Q2 showed why the bull case exists: $206M of revenue, gross profit of $36M versus -$12M a year ago, and EBITDA margin of 8.2%. The company is clearly moving from one-off mission hype toward scaled manufacturing and infrastructure deployment.

The problem is the stock is not priced for a company that is merely becoming viable. At $15.62 and $2.2B market cap, investors are still paying for a future in which backlog converts smoothly, margins keep rising, and the company becomes a durable cislunar infrastructure platform. Yet the actual reported base is still messy: FY2025 revenue was only $0.2B, operating margin was -28.5%, net margin -90.8%, EPS -$0.70, and free cash flow -$0.1B. Q2 operating cash use was $60M, and that was after the business had already raised $235M via ATM to bring cash to $367M. That is not distress, but it is not self-funding either.

The case depends on three things. First, management must prove the FY26 guide is real, not just book-to-bill strength with delayed revenue recognition. Second, positive adjusted EBITDA needs to turn into a credible path to free cash flow as capex and working capital normalize. Third, the market has to believe NSNS and the IM-300 platform create repeatable economics, not just lumpy aerospace project revenue. Those are possible outcomes, but they are not yet earned enough to justify a premium 4.61x sales multiple against a 3.1x peer average.

The stock being -66.6% off its 52-week high cuts both ways. It removes some mania. It also shows how much execution faith has already been lost. If November results show clean conversion toward the $900M-$1.0B guide and materially better cash flow, the view can change fast. Until then, the more likely mistake is paying too much for backlog before it becomes cash and earnings.

Key Metrics

Financial Strength

The balance sheet is good enough for the next phase, but not yet good enough to remove financing risk from the story. Cash of $367M and a 1.66 current ratio give LUNR runway, especially after the Q2 ATM raise, but that strength came from equity issuance rather than internal funding. Total debt of $0.4B, negative free cash flow, and $60M of Q2 operating cash use show the business still needs working-capital discipline and project execution to become sustainably financeable on its own. Margin direction improved sharply in Q2, but one quarter of positive adjusted EBITDA does not outweigh a FY2025 operating margin of -28.5% and net margin of -90.8%.

Competitive Position

The moat is real but still forming. LUNR has flight heritage in lunar missions, embedded relationships in NASA and national space programs, and a potentially sticky infrastructure position through NSNS, where once relay, navigation, and mission operations are deployed, switching costs can rise. The durability question is whether that turns into recurring network economics or stays as discrete contract work, and that answer is still unproven given current cash burn and project volatility.

Management & Guidance

Management is guiding to $900M-$1.0B of FY26 revenue and positive adjusted EBITDA, with CEO Stephen Altemus saying, "Based on that visibility, we are reaffirming and remain confident in our $900 million to $1 billion revenue outlook and our expectation for positive adjusted EBITDA for the full year." The guide is supported by a $1.8B backlog, $1.7B of bookings YTD, and an expected $300M of additional 2H26 ATP bookings, but credibility is only moderate because guidance was reaffirmed rather than raised and contract definitization still affects timing. CFO Peter McGrath also said, "Free cash flow is expected to improve throughout the second half of the year as investments stabilize and milestone receivables come in following our recent awards." Given the recent miss pattern and Q2 cash burn, that improvement needs to show up in reported cash flow, not just backlog commentary.

Segment Analysis

• Lunar access services and CLPS-related programs (Not disclosed): Mission awards remain a major revenue source, with IM-4 charges showing project-level volatility.
• Satellite manufacturing and NSNS infrastructure (Not disclosed): This was a key driver of the $206M Q2 revenue surge and underpins the 70-plus IM-300 contracted spacecraft.
• OMES and other space services (Not disclosed): Historically important, but management previously flagged OMES revenue rolling down as newer lunar and communications programs ramp.
• Geography (Primarily U.S. government and U.S.-linked contracts): Revenue concentration appears heavily tied to NASA and adjacent U.S. space infrastructure spending.

Capital Allocation

Capital allocation is aggressive and growth-first. Management raised $235M through an ATM in Q2, lifting cash to $367M, then directed capex of $24M mainly into the NSNS constellation and ground segment while also bringing 75,000 sq. ft. of Houston space online. There are no buybacks or dividends, which is appropriate for a company with FCF -$0.1B, but the discipline test is whether these investments start reducing, not extending, dependence on external capital.

Management Execution & Track Record

Management has executed well on commercial traction and poorly on earnings consistency. On the 2024 Q3 call, management narrowed FY24 revenue to $215M-$235M, highlighted $316.2M backlog, $106.9M expected year-end cash, and projected IM-2 in Q1 2025 and IM-3 in early 2026 with NSNS beginning to contribute. By the 2026 Q2 call, backlog had expanded to $1.8B, cash rose to $367M, and FY26 guidance reached $900M-$1.0B with positive adjusted EBITDA, so the growth strategy clearly scaled. But credibility is capped by the earnings record, with 6 misses in the last 8 quarters, including very large misses in May and August 2026, continued negative free cash flow, and a balance sheet that went from zero debt in late 2024 to $0.4B total debt now. The direction has not changed materially, build lunar and space infrastructure at scale, but the market should treat management as strong at winning work and less proven at converting that work into predictable profits and cash.

Positioning & Flows

Ownership is tight enough to keep volatility high, with the top 3 institutions holding 61.2% and insiders holding 36.6%. Short interest is elevated at 27.48%, or 35.5M shares on a 129M float with 3 days-to-cover, so sharp squeezes are possible, especially with the stock already -66.6% below its 52-week high. Options positioning is mildly supportive near spot, with positive GEX and zero-gamma at $14.35, but that is trading texture, not a reason to underwrite fundamentals at this valuation.

Bull Case

• Q2 2026 revenue was $206M, up more than 4x Y/Y, with growth driven by satellite manufacturing, CLPS, NSNS and OMES execution.
• Backlog reached $1.8B after $920M of new Q2 bookings, and management expects 25%-30% backlog conversion in 2026 and 35%-40% in 2027.
• Adjusted EBITDA was $0.02B in Q2 with an 8.2% margin, improving 2,670 bps from Q1 and 8,260 bps from the prior-year Q2.
• More than 70 IM-300 spacecraft under contract and 75,000 sq. ft. of new Houston capacity give the company a real shot at manufacturing scale.

Bear Case

• FY2025 fundamentals remain weak, EPS -$0.70, operating margin -28.5%, net margin -90.8%, and FCF -$0.1B, which is a poor base for a $2.2B market cap.
• Execution credibility is mixed at best, with EPS misses in 6 of the last 8 reported quarters, including -220.9% on 2026-08-13 and -485.1% on 2026-05-14.
• Guidance was only reaffirmed, not raised, despite the booking surge, and management explicitly tied revenue to contract definitization timing.
• The capital structure has become more dependent on equity financing, with total debt $0.4B versus zero debt on the 2024 Q3 call, and the recent $235M ATM diluted holders to fund growth.

Valuation & Price Target

Engine price target $7.18 (-54% vs current), Low confidence.

• P/S Multiple: $3.76 (45% weight)
• Quality-adjusted: $14.87 (20% weight)

This call aligns with the quant baseline of SELL (Low conviction), but with slightly higher conviction because the disconnect between operating momentum and valuation still looks unresolved. The engine target is $7.18, based on a low-confidence sales-quality blend, and that makes sense given the split between a $3.76 P/S-derived value and $14.87 quality-adjusted value. The quality score is only 44/100, risk is 55/100 (Moderate), peer dispersion is wide at 4.1x, and LUNR still trades at 4.61x sales versus peers at 3.1x despite FY2025 EPS -$0.70, operating margin -28.5%, and FCF -$0.1B. Sell-side consensus is Strong Buy (4 buy / 0 hold / 0 sell), but that is a low-signal context item here and is hard to square with repeated earnings misses, equity-funded liquidity, and a valuation that already discounts a large part of the FY26 ramp.

Risk Assessment

Risk score 55/100 (Moderate). The biggest risk to the bearish call is that LUNR converts its $1.8B backlog and $300M of expected 2H26 ATP bookings into revenue and sustained positive EBITDA faster than expected, forcing the market to look through current losses.

The Bottom Line

LUNR rates SELL, Medium conviction. The company is building something strategically important and its booking momentum is real, but the stock still gives too much credit for future conversion, margin durability, and cash generation that have not yet been proven. At $15.62, the shares sit far above the $7.18 quant target even after a brutal drawdown from the highs. The thesis changes if November results show clean progress toward the $900M-$1.0B guide and a much better cash profile. Until then, this is a story where fundamentals are improving, but valuation still runs ahead of proof.